DA-8010 clinical trials
Also written DA-8010.
How each study uses DA-8010 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Cholinergic Antagonists source
- One of Antimuscarinics source
Studies
Open first, then newest update. How each study uses DA-8010 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive BladderCompletedPhase 3Dong-A ST Co., Ltd.NCT05282069Written as DA-8010 2.5mg
- A Study to Evaluate the Effects of Renal Function on Pharmacokinetics and Safety of DA-8010CompletedPhase 1Dong-A ST Co., Ltd.NCT05812417Written as DA-8010
- Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy AdultsCompletedPhase 1Dong-A ST Co., Ltd.NCT05991401Written as DA-8010 5mg
- Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy AdultsCompletedPhase 1Dong-A ST Co., Ltd.NCT05992428Written as DA-8010 5mg
- The Food Effect on Pharmacokinetics of DA-8010 After a Single Administration of DA-8010 2.5 mg or 5 mg in Healthy SubjectsCompletedPhase 1Dong-A ST Co., Ltd.NCT04686825Written as DA-8010 2.5mg (Fasting)
- A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive BladderCompletedPhase 2Dong-A ST Co., Ltd.NCT03566134Written as DA-8010 2.5mg
- A Study to Evaluate Safety, Tolerability and Pharmacokinetics of DA-8010 in Healthy SubjectsStatus unknownPhase 1Dong-A ST Co., Ltd.NCT02821312Written as DA-8010
Codes
What other systems call DA-8010 · ClinicalTrials.gg INT001078
- MeSH (NLM) C000630740DA-8010One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000630740 | DA-8010 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.